AP NEWS
Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 6, 2019
Portola Pharmaceuticals, Inc. Logo (PRNewsfoto/Portola Pharmaceuticals, Inc.®)
Portola Pharmaceuticals, Inc. Logo (PRNewsfoto/Portola Pharmaceuticals, Inc.®)

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update.

“We delivered another quarter of strong Andexxa revenue in the U.S. and expanded our growth potential with our first sales of Ondexxya in Europe. The use of Factor Xa inhibitors in both markets continues to grow, driving the underlying market opportunity for Andexxa/Ondexxya and long-term value of Portola,” said Scott Garland, Portola’s president and chief executive officer. “Looking forward, we will continue to focus on exceptional launch execution, leveraging external support from health authorities and favorable society guidelines, and building the clinical evidence and awareness of Andexxa. In addition, we remain on track to initiate a registration trial for cerdulatinib in early 2020 and will present updated data at the ASH meeting in December.”

Product Sales:

Operating Expenses:

For the third quarter of 2019, compared to the same period in 2018:



Three Months Ended September 30,


Nine Months Ended September 30,

(In thousands)


2019


2018


2019


2018

Cost of Sales


$

2,684



$

4,292



$

14,825



$

5,680


Non-GAAP cost of sales


$

2,684



$

4,292



$

10,876



$

5,680











Research and development expenses


$

25,647



$

40,237



$

94,769



$

166,744


Non-GAAP research and development expenses


$

21,916



$

35,858



$

68,358



$

152,593











Selling, general and administrative expenses


$

52,050



$

38,792



$

158,939



$

110,547


Non-GAAP selling, general and administrative expenses


$

44,735



$

31,778



$

135,183



$

89,111











Totaling operating expenses


$

80,381



$

83,321



$

268,533



$

282,971


Non-GAAP Total operating expenses


$

69,335



$

71,928



$

214,416



$

247,384


Cash, Cash Equivalents and Investments:

Recent Achievements and Events

Planned Upcoming Milestones

Analyst and Investor Meeting

Portola will host an analyst and investor meeting focused on Andexxa on Thursday, November 14, 2019, from 8:00 to 10:30 a.m. ET in New York. Seating is limited to those who RSVP. Please contact events@portola.com for an invitation. The event will also be webcast live and can be accessed live on the Investor Relations section of the Company’s website at http://investors.portola.com. It will be archived for one year following the date of the event.

Conference Call Details

Portola will host a conference call today, Tuesday, November 5, 2019, at 4:30 p.m. ET, during which time management will discuss the third quarter 2019 financial results, updates on the U.S. and European launch of Andexxa/Ondexxya, and its operations. The live call can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 2980632. The webcast can be accessed live on the Investor Relations section of the Company’s website at http://investors.portola.com. It will be archived for 30 days following the call.

Use of Non-GAAP Financial Measures

This press release and the reconciliation table included herein include non-GAAP R&D expenses. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations. When viewed in conjunction with GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance and are better able to compare the Company’s performance between periods. In addition, these non-GAAP financial measures are among those that the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation of GAAP to non-GAAP financial measures is provided in the accompanying table entitled “Reconciliation of GAAP to Non-GAAP Financial Information.”

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company’s first two commercialized products are Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya (andexanet alfa), and Bevyxxa (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the anticipated initiation of a registrational trial for cerdulatinib in PTCL, the growing demand for our products, our continued commercial launch for Ondexxya in Europe, our ability to leverage external support from health authorities and build clinical evidence and awareness of Andexxa and our plans to present new data and continue development of our products and product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the risk that physicians, patients and payers may not see the benefits of utilizing Andexxa for the indications for which it is approved; our ability to continue to manufacture our products and to expand approved manufacturing facilities; the possibility of unfavorable results from additional clinical trials involving Andexxa; our ability to grow our commercial operations in the EU and generate product revenue within projected timelines and budget; the risk that we may not obtain additional regulatory approvals necessary to expand approved indications for Andexxa; our expectation that we will incur losses for the foreseeable future and will need additional funds to finance our operations; the accuracy of our estimates regarding expenses and capital requirements; our ability to successfully build a hospital-based sales force and commercial infrastructure; our ability to obtain and maintain intellectual property protection for our product candidates; and our ability to retain key scientific or management personnel. These and other risks and uncertainties are described more fully in our most recent filings with the Securities and Exchange Commission, including our most recent quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Unaudited Condensed Consolidated Statements of Operations


(In thousands, except share and per share data)




Three Months Ended September 30,


Nine Months Ended September 30,



2019


2018


2019


2018

Revenues:









Product revenue, net


$

35,743



$

7,176



$

83,269



$

10,047


Collaboration and license revenue


1,056



7,001



4,123



14,785


Total revenues


36,799



14,177



87,392



24,832


Operating expenses:









Cost of sales


2,684



4,292



14,825



5,680


Research and development


25,647



40,237



94,769



166,744


Selling, general and administrative


52,050



38,792



158,939



110,547


Total operating expenses


80,381



83,321



268,533



282,971


Loss from operations


(43,582)



(69,144)



(181,141)



(258,139)


Interest and other income, net


1,953



3,924



7,958



9,123


Interest expense


(7,998)



(5,957)



(23,017)



(12,642)


Net loss


(49,627)



(71,177)



(196,200)



(261,658)


Net (income) loss attributable to noncontrolling interest




(126)



2,213



(17)


Net loss attributable to Portola


$

(49,627)



$

(71,303)



$

(193,987)



$

(261,675)


Net loss per share attributable to Portola common stockholders:









Basic and diluted


$

(0.68)



$

(1.08)



$

(2.79)



$

(3.97)


Shares used to compute net loss per share attributable to Portola common stockholders:









Basic and diluted


73,017,609



66,165,104



69,427,124



65,855,672


Unaudited Condensed Consolidated Balance Sheet Data


(In thousands)




September 30, 2019


December 31, 2018



(Unaudited)

Cash, cash equivalents and investments


$

476,807



$

316,964


Trade and other receivables, net


18,236



5,849


Unbilled - collaboration and license revenue


3,788



9,880


Inventories


2,357



7,873


Property and equipment, net


4,561



5,236


Intangible assets


3,699



7,279


Other assets


67,737



33,338


Total assets


577,185



386,419


Total current liabilities


87,491



69,005


Long-term liabilities


276,806



226,847


Total stockholders' equity


212,888



90,567


Total liabilities and stockholders' equity


577,185



386,419


PORTOLA PHARMACEUTICALS, INC.


Reconciliation of GAAP to Non-GAAP Financial Information


(In thousands, except for per share data)




Three Months Ended September 30,


Nine Months Ended September 30,



2019


2018


2019


2018

Reconciliation of cost of sales:









GAAP cost of sales


$

2,684



$

4,292



$

14,825



$

5,680


Gen1 transition






(3,949)




Non-GAAP cost of sales


$

2,684



$

4,292



$

10,876



$

5,680











Reconciliation of research and development:









GAAP research and development


$

25,647



$

40,237



$

94,769



$

166,744


Stock-based compensation expense


(3,731)



(4,379)



(17,437)



(14,151)


SRX intangible impairment






(3,151)




Equity valuation to manufacturer






(5,824)




Non-GAAP research and development expenses


$

21,916



$

35,858



$

68,358



$

152,593











Reconciliation of selling, general and administrative expenses:









GAAP selling, general and administrative expenses


$

52,050



$

38,792



$

158,939



$

110,547


Stock-based compensation expense


(7,315)



(7,014)



(23,756)



(21,436)


Non-GAAP selling, general and administrative expenses


$

44,735



$

31,778



$

135,183



$

89,111











Reconciliation of total operating expenses:









GAAP total operating expenses


$

80,381



$

83,321



$

268,533



$

282,971


Gen1 transition






(3,949)




Stock-based compensation expense


(11,046)



(11,393)



(41,193)



(35,587)


SRX intangible impairment






(3,151)




Equity valuation to manufacturer






(5,824)




Non-GAAP total operating expenses


$

69,335



$

71,928



$

214,416



$

247,384











Reconciliation of net loss attributable to Portola:









GAAP net loss attributable to Portola shareholders


$

(49,627)



$

(71,303)



$

(193,987)



$

(261,675)


Gen1 transition






3,949




Stock-based compensation expense


11,046



11,393



41,193



35,587


SRX intangible impairment






3,151




Equity valuation to manufacturer






5,824




Non-GAAP net loss attributable to Portola shareholders


$

(38,581)



$

(59,910)



$

(139,870)



$

(226,088)











Reconciliation of diluted net loss per share:









GAAP net loss per share


$

(0.68)



$

(1.08)



$

(2.79)



$

(3.97)


Gen1 transition






0.06




Stock-based compensation expense


0.15



0.17



0.59



0.54


SRX intangible impairment






0.05




Equity valuation to manufacturer






0.08




Non-GAAP net loss per share


$

(0.53)



$

(0.91)



$

(2.01)



$

(3.43)











Shares used to compute loss per share


73,018



66,165



69,427



65,856











Non-GAAP adjustment summary:









Cost of sales


$



$



$

(3,949)



$


Research and development


(3,731)



(4,379)



(26,412)



(14,151)


Selling, general and administrative expenses


(7,315)



(7,014)



(23,756)



(21,436)


Total non-GAAP adjustments


$

(11,046)



$

(11,393)



$

(54,117)



$

(35,587)


View original content to download multimedia: http://www.prnewswire.com/news-releases/portola-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-corporate-update-300952145.html

SOURCE Portola Pharmaceuticals, Inc.®